Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).

1 finding from 1 review

Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
RR 0.45 [0.3, 0.67]
9 studies · 1119 participants
Moderate

Aldosterone antagonists vs placebo or usual care

All cardiovascular death · people with chronic kidney disease requiring dialysis

Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).

1 finding from 1 review

Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
RR 0.37 [0.22, 0.64]
6 studies · 908 participants
Moderate

Aldosterone antagonists vs placebo

Death (any cause) ( · heart failure with chronic kidney disease

It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
RR 0.61 [0.06, 6.59]
2 studies · 34 participants
Very low

Aldosterone antagonists vs placebo

Cardiovascular mortality · heart failure with chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found